-
Time from stopping blood thinner to bypass surgery may be shortened for select patients
[ad_1] Research Highlights: The medication ticagrelor is a common anti-platelet medication prescribed to prevent blood clotting after a heart attack.…
Read More » -
3DX Accepts Bitcoin and Ethereum for Manufacturing Projects
[ad_1] Seattle – (NewMediaWire) – November 12, 2021 – 3DX Industries Inc. (DDDX) (the “Company” or “3DX”), a state of the…
Read More » -
Dewmar International Announces the Public Availability of its Disclosure Document and its Financial Statement for the Period Ended September 30, 2021
[ad_1] New York, NY – (NewMediaWire) – November 12, 2021 – Dewmar International BMC Inc. announced today that its complete…
Read More » -
Society Pass (SoPa) Announces Closing of $26,000,000 Initial Public Offering and Closing of $2,125,000 Over-Allotment
[ad_1] Singapore – (NewMediaWire) – November 12, 2021 – Society Pass Incorporated (Nasdaq: SOPA) (“SoPa” or the “Company”), a leading…
Read More » -
News
AppSwarm Announces Agreement with Renavotio, Inc. (OTCQB:RIII) for Infrastructure and Smart City Development
[ad_1] Tulsa, OK – (NewMediaWire) – November 12, 2021 – AppSwarm, Corp. (OTC: SWRM), a software development company and aggregator of…
Read More » -
GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update
[ad_1] Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs Atlanta, GA – (NewMediaWire) – November 11, 2021 – GeoVax…
Read More » -
Forian Inc. Announces Third Quarter Fiscal 2021 Financial Results
[ad_1] Third Quarter Revenue of $5.0 Million, Up $4.8 Million Year-Over-Year,Pro Forma Year-Over-Year Growth of 62% Newtown, PA – (NewMediaWire)…
Read More » -
News
Hop-On, Inc., Acquires Vertuoso To Integrate Company’s Expertise With Vertical Story-Telling Into Hop-On’s Digitalage Platform
[ad_1] Temecula, CA – (NewMediaWire) – November 11, 2021 – Hop-on, Inc. (OTC:HPNN,) an international leader in the development and…
Read More » -
Featured
Pasithea Therapeutics: A High-Potential Biopharma
The market is betting on ketamine’s exciting potential as a market-leading antidepressant and treatment for other treatment-resistant psychiatric disorders. It…
Read More »
